Botulinum toxin-A beneficial in painful diabetic neuropathy

Botulinum toxin-A beneficial in painful diabetic neuropathy

(HealthDay)—Botulinum toxin-A (BTX-A) appears to be beneficial for painful diabetic neuropathy (PDN), according to a meta-analysis published online March 20 in Pain Medicine.

Shaheen E. Lakhan, M.D., Ph.D., from the Global Neuroscience Initiative Foundation in Los Angeles, and colleagues conducted a meta-analysis of two studies using BTX-A in the treatment of . The difference in visual analog scale (VAS) from pre-intervention to one month post-intervention was measured as the primary outcome.

The researchers found that following treatment with BTX-A there was an improvement of 1.96 VAS points (P < 0.001), which corresponded to a clinically significant improvement of "minimum change in pain." There was no statistically significant effect on adverse events in terms of infection at injection site (P = 0.49).

"Tests for significance, low overall risk of bias, and almost no statistical heterogeneity suggests that there is a correlation between BTX-A and improvement of in PDN," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Botulinum toxin-A beneficial in painful diabetic neuropathy (2015, April 3) retrieved 13 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Pre-op back pain, pain sensitivity predict outcomes


Feedback to editors